Press Release: Nextrove to Host 2026 China Annual Conference Focused on the Future of Pharmacovigilance
Global Experience. Local Precision. Advancing Pharmacovigilance
About Nextrove
Nextrove leads the industry in Pharmacovigilance Professional Services and Solutions. Our unwavering mission, “Empowering Clients to Improve Patient Safety,” propels us on the path to realizing our vision of becoming the first choice for Life Sciences professional services and solutions, in service of our clients, partners, and, above all, the patients we ultimately serve.
www.nextrove.com
info@nextrove.com
+1 347 551 1700
Nextrove LLC.
116 Village Boulevard,
Princeton Forrestal Village, Suite 208
Princeton, NJ 08540, USA
Nextrove China
2 / F, 2900 Nanxingang Road,
Fengxian District,
Shanghai
China
Shanghai, China — Nextrove has announced the 2026 Nextrove China Annual Conference, a two-city event that will take place in Shanghai on September 8 and Beijing on September 10, 2026, bringing together professionals from across the life sciences industry to discuss the evolving landscape of pharmacovigilance.
Held under the theme “Global Experience. Local Precision. Advancing Pharmacovigilance,” the conference will provide a forum for dialogue on the challenges and opportunities shaping modern drug safety. The program will feature industry experts, regulatory professionals, technology leaders, and pharmacovigilance specialists sharing practical experiences, emerging trends, and perspectives on the future of safety operations.
As regulatory requirements continue to evolve and organizations increasingly embrace digital transformation, the event will explore how companies are balancing global standards with local regulatory expectations while integrating innovative technologies into their pharmacovigilance strategies.
The agenda will include presentations, customer case studies, panel discussions, and networking sessions covering topics such as regulatory compliance, operational excellence, AI-enabled pharmacovigilance, cloud transformation, inspection readiness, and the practical application of new technologies across the safety ecosystem.
“Digital transformation is redefining the future of Pharma. The challenge is embracing it without compromising quality, compliance, or patient safety.” said Ratika Dhar, Chief Strategy Officer at Nextrove. “This conference has been designed to encourage open dialogue, knowledge sharing, and collaboration across the industry, creating opportunities to exchange practical experiences and discuss the innovations that are shaping the future of drug safety.”
The conference is expected to welcome representatives from pharmaceutical companies, biotechnology organizations, CROs, regulatory affairs teams, safety operations, quality organizations, and technology partners from across China and the broader Asia-Pacific region.
With its combination of strategic discussion and practical insight, the 2026 Nextrove China Annual Conference aims to foster collaboration across the pharmacovigilance community while highlighting approaches that support compliant, efficient, and future-ready safety operations.
Additional information, including the full agenda, speaker lineup, venue details, and registration, will be released in the coming weeks.
Event Dates & Times
- Shanghai: Wednesday, September 8, 2026
- Beijing: Friday, September 10, 2026
Registration is now open
Join us as we lead the global transformation of pharmacovigilance—starting from China.
Stay tuned — additional speaker details and session topics will be announced soon.
Nextrove Launches Quarterly Pharmacovigilance and Regulatory Intelligence Bulletin
To help organizations stay ahead of the rapidly evolving global regulatory landscape, Nextrove is introducing its Quarterly Pharmacovigilance and Regulatory Intelligence Bulletin—a new service designed to provide timely, actionable insights into the latest pharmacovigilance and drug safety developments worldwide.
Published every quarter, the bulletin delivers a concise overview of key regulatory updates, newly released guidance documents, inspection trends, and emerging expectations from major global health authorities. It also highlights changes that may impact pharmacovigilance systems, reporting requirements, operational processes, and compliance strategies.
Designed for pharmacovigilance professionals, regulatory affairs teams, quality organizations, and senior leadership, the bulletin helps clients proactively assess regulatory changes, anticipate future requirements, and strengthen global compliance efforts.
By transforming complex regulatory updates into practical business intelligence, Nextrove continues its commitment to helping life sciences organizations navigate change with confidence while maintaining the highest standards of patient safety and regulatory excellence.
PACE: Progressive Adoption and Cloud Evolution - Advancing Safety at Your Pace
Emerging life sciences organizations face a common challenge: how to build a compliant, scalable pharmacovigilance (PV) function without investing in a large, complex infrastructure before being ready.
PACE (Progressive Adoption and Cloud Evolution) is a fully scalable pharmacovigilance operating ecosystem designed specifically for growing life sciences organizations. More than a product or software platform, PACE is a client lifecycle ecosystem that enables companies to establish, scale, and mature their safety operations through a flexible, AI-enabled, compliance-ready cloud environment.
Built for Realities
Growing life sciences organizations often face significant operational challenges:
- Limited or non-existent PV infrastructure
- Small or developing internal safety teams
- Increasing regulatory expectations
- Budget constraints
- Unpredictable growth trajectories
- Long implementation timelines associated with enterprise systems
Traditional enterprise solutions often require substantial upfront investment and resources, forcing organizations to overbuild capabilities long before they are needed.
PACE takes a different approach.
Simplicity + Speed + Scalability
No need to build a massive pharmacovigilance infrastructure before being ready.
PACE enables organizations to adopt the right level of PV capability at the right stage of growth, allowing teams to remain agile while maintaining compliance and operational excellence.
Flexible Deployment Across Cloud and On-Premise Environments
Essentials
Foundation Phase: Start Safely
Ideal for:
- Pre-clinical companies
- Early clinical programs
- Lean biotech teams
Core value:
Establish a compliant pharmacovigilance foundation rapidly and cost-effectively, providing the critical infrastructure needed to support early development activities.
Efficiencies
Acceleration Phase: Automate Intelligently
Ideal for:
- Expanding clinical programs
- Increasing case volumes
- Growing operational demands
Core value:
Automate workflows, streamline processes, and reduce operational burden while scaling globally through cloud-enabled technologies and intelligent automation.
Excellence
Enterprise Readiness Phase: Scale Strategically
Ideal for:
- Late-stage biotech organizations
- Commercialization readiness
- Marketed product portfolios
Core value:
Achieve operational excellence through a fully integrated, AI-powered pharmacovigilance ecosystem capable of supporting global compliance and long-term growth.
By combining simplicity, speed, and scalability, PACE helps companies establish regulatory readiness, optimize operations, and seamlessly evolve into enterprise-grade pharmacovigilance without the disruption, cost, or complexity of rebuilding systems as they grow
PACE: Advancing Safety at Your Pace.